ASC, a bioactive steroidal saponin from Ophitopogin japonicas, inhibits angiogenesis through interruption of src tyrosine kinase-dependent matrix metalloproteinase pathway

Basic and Clinical Pharmacology and Toxicology

Volumn 116, Issue 2, 2015, Pages 115-123

  Zeng, Ke Wu ^a   Song, Fang Jiao ^b   Li, Ning ^a   Dong, Xin ^a   Jiang, Yong ^a   Tu, Peng Fei ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b PEKING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ASC; AXITINIB; CD31 ANTIGEN; CYCLIN B1; GELATINASE A; GELATINASE B; HERBACEOUS AGENT; MATRIX METALLOPROTEINASE; PROTEIN TYROSINE KINASE; SAPONIN; UNCLASSIFIED DRUG; VASCULOTROPIN; OPHIOPOGON ROOT;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL DIVISION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CHINESE HERB; CONCENTRATION RESPONSE; CONTROLLED STUDY; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OPHITOPOGIN JAPONICAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR INVASION; UMBILICAL VEIN ENDOTHELIAL CELL; ANIMAL; C57BL MOUSE; CHEMISTRY; DOWN REGULATION; DRUG EFFECTS; GENETICS; ISOLATION AND PURIFICATION; M PHASE CELL CYCLE CHECKPOINT; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC;

MUS;

ANGIOGENESIS INHIBITORS; ANIMALS; DOWN-REGULATION; G2 PHASE CELL CYCLE CHECKPOINTS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; M PHASE CELL CYCLE CHECKPOINTS; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; OPHIOPOGON; SAPONINS; SRC-FAMILY KINASES;

EID: 84921305027     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/bcpt.12305     Document Type: Article

References (45)

1. Lammers PE, Horn L. Targeting angiogenesis in advanced non-small cell lung cancer. J Natl Compr Canc Netw 2013;11:1235-47.
2. Bruno A, Pagani A, Magnani E, Rossi T, Noonan DM, Cantelmo AR et al. Inflammatory angiogenesis and the tumor microenvironment as targets for cancer therapy and prevention. Cancer Treat Res 2014;159:401-26.
3. Dimova I, Popivanov G, Djonov V. Angiogenesis in cancer-general pathways and their therapeutic implications. J BUON 2014;19:15-21.
4. Al-Husein B, Abdalla M, Trepte M, Deremer DL, Somanath PR. Antiangiogenic therapy for cancer: an update. Pharmacotherapy 2012;32:1095-111.
5. Gerhardt H. VEGF and endothelial guidance in angiogenic sprouting. Organogenesis 2008;4:241-6.
6. Rehders A, Stoecklein NH, Guray A, Riediger R, Alexander A, Knoefel WT. Vascular invasion in pancreatic cancer: Tumor biology or tumor topography? Surgery 2012;152:S143-51.
7. Hiratsuka S. Vasculogenensis, angiogenesis and special features of tumor blood vessels. Front Biosci 2011;16:1413-27.
8. Horsman MR, Bohn AB, Busk M. Vascular targeting therapy: potential benefit depends on tumor and host related effects. Exp Oncol 2010;32:143-8.
9. El-Kenawi AE, El-Remessy AB. Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales. Br J Pharmacol 2013;170:712-29.
10. Sakurai T, Kudo M. Signaling pathways governing tumor angiogenesis. Oncology 2011;81(Suppl 1):24-9.
11. Brakenhielm E, Cao RH, Cao YH. Suppression of angiogenesis, tumor growth, and wound healing by resveratrol, a natural compound in red wine and grapes. FASEB J 2001;15:1789-800.
12. Sagar SM, Yance D, Wong RK. Natural health products that inhibit angiogenesis: a potential source for investigational new agents to treat cancer-Part 1. Curr Oncol 2006;13:14-26.
13. Yeh JC, Cindrova-Davies T, Belleri M, Morbidelli L, Miller N, Cho CW et al. The natural compound n-butylidenephthalide derived from the volatile oil of Radix Angelica sinensis inhibits angiogenesis in vitro and in vivo. Angiogenesis 2011;14:187-97.
14. Li N, Zhang L, Zeng KW, Zhou Y, Zhang JY, Che YY et al. Cytotoxic steroidal saponins from Ophiopogon japonicas. Steroids 2013;78:1-7.
15. Roh YJ, Park YG, Kang S, Kim SY, Moon JI. Effects of AFP-172 on COX-2-induced angiogenic activities on human umbilical vein endothelial cells. Graefes Arch Clin Exp Ophthalmol 2012;250:1765-75.
16. Zhang HC, Liu XB, Huang S, Bi XY, Wang HX, Xie LX et al. Microvesicles derived from human umbilical cord mesenchymal stem cells stimulated by hypoxia promote angiogenesis both in vitro and in vivo. Stem Cell Dev 2012;21:3289-97.
17. Hervé MA, Buteau-Lozano H, Mourah S, Calvo F, Perrot-Applanat M. VEGF189 stimulates endothelial cells proliferation and migration in vitro and up-regulates the expression of Flk-1/KDR mRNA. Exp Cell Res 2005;309:24-31.
18. Zhu W, Fu A, Hu J, Wang T, Luo Y, Peng M et al. 5-Formylhonokiol exerts anti-angiogenesis activity via inactivating the ERK signaling pathway. Exp Cell Res 2011;43:146-52.
19. Li Y, Wang H, Yang B, Yang J, Ruan X, Yang Y et al. Influence of carbon monoxide on growth and apoptosis of human umbilical artery smooth muscle cells and vein endothelial cells. Int J Biol Sci 2012;8:1431-46.
20. Tang JY, Li S, Li ZH, Zhang ZJ, Hu G, Cheang LC et al. Calycosin promotes angiogenesis involving estrogen receptor and mitogen-activated protein kinase (MAPK) signaling pathway in zebrafish and HUVEC. PLoS ONE 2010;5:e11822.
21. Passaniti A, Taylor RM, Pili R, Guo Y, Long PV, Haney JA et al. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab Invest 1992;67:519-28.
22. King JW, Lee SM. Axitinib for the treatment of advanced non-small-cell lung cancer. Expert Opin Investig Drugs 2013;22:765-73.
23. Toffoli G, De Mattia E, Cecchin E, Biason P, Masier S, Corona G. Pharmacology of epidermal growth factor inhibitors. Int J Biol Markers 2007;22:S24-39.
24. Hendrix A, Gespach C, Bracke M, De Wever O. The tumor ecosystem regulates the roads for invasion and metastasis. Clin Res Hepatol Gastroenterol 2011;35:714-9.
25. Hua H, Li M, Luo T, Yin Y, Jiang Y. Matrix metalloproteinases in tumorigenesis: an evolving paradigm. Cell Mol Life Sci 2011;68:3853-68.
26. Auerbach R, Lewis R, Shinners B, Kubai L, Akhtar N. Angiogenesis assays: a critical overview. Clin Chem 2003;49:32-40.
27. Singh S, Sadanandam A, Singh RK. Chemokines in tumor angiogenesis and metastasis. Cancer Metastasis Rev 2007;26:453-67.
28. Moserle L, Casanovas O. Anti-angiogenesis and metastasis: a tumour and stromal cell alliance. J Intern Med 2013;273:128-37.
29. Alessi P, Ebbinghaus C, Neri D. Molecular targeting of angiogenesis. Biochim Biophys Acta 2004;1654:39-49.
30. Longo R, Sarmiento R, Fanelli M, Capaccetti B, Gattuso D, Gasparini G. Anti-angiogenic therapy: rationale, challenges and clinical studies. Angiogenesis 2002;5:237-56.
31. Vacca A, Ribatti D, Iurlaro M, Albini A, Minischetti M, Bussolino F et al. Human lymphoblastoid cells produce extracellular matrix degrading enzymes and induce endothelial cell proliferation, migration, morphogenesis, and angiogenesis. Int J Clin Lab Res 1998;28:55-68.
32. Szubert S, Szpurek D, Moszynski R, Nowicki M, Frankowski A, Sajdak S et al. Extracellular matrix metalloproteinase inducer (EMMPRIN) expression correlates positively with active angiogenesis and negatively with basic fibroblast growth factor expression in epithelial ovarian cancer. J Cancer Res Clin Oncol 2014;140:361-9.
33. Rundhaug JE. Matrix metalloproteinases and angiogenesis. J Cell Mol Med 2005;9:267-85.
34. Arroyo AG, Genis L, Gonzalo P, Matías-Román S, Pollán A, Gálvez BG. Matrix metalloproteinases: New routes to the use of MT1-MMP as a therapeutic target in angiogenesis-related disease. Curr Pharm Des 2007;13:1787-802.
35. Littlepage LE, Sternlicht MD, Rougier N, Phillips J, Gallo E, Yu Y et al. Matrix metalloproteinases contribute distinct roles in neuroendocrine prostate carcinogenesis, metastasis, and angiogenesis progression. Cancer Res 2010;70:2224-34.
36. Giannopoulos G, Pavlakis K, Parasi A, Kavatzas N, Tiniakos D, Karakosta A et al. The expression of matrix metalloproteinases-2 and -9 and their tissue inhibitor 2 in pancreatic ductal and ampullary carcinoma and their relation to angiogenesis and clinicopathological parameters. Anticancer Res 2008;28:1875-81.
37. Kalishwaralal K, Sheikpranbabu S, BarathManiKanth S, Haribalaganesh R, Ramkumarpandian S, Gurunathan S. Gold nanoparticles inhibit vascular endothelial growth factor-induced angiogenesis and vascular permeability via Src dependent pathway in retinal endothelial cells. Angiogenesis 2011;14:409-10.
38. Chen J, Elfiky A, Han M, Chen C, Saif MW. The role of Src in colon cancer and its therapeutic implications. Clin Colorectal Cancer 2014;13:5-13.
39. Cheng JQ, Lindsley CW, Cheng GZ, Yang H, Nicosia SV. The Akt/PKB pathway: molecular target for cancer drug discovery. Oncogene 2005;24:7482-92.
40. Cheng GZ, Park S, Shu S, He L, Kong W, Zhang W et al. Advances of AKT pathway in human oncogenesis and as a target for anti-cancer drug discovery. Curr Cancer Drug Targets 2008;8:2-6.
41. Lee CW, Yang CM. TNF-alpha-induced MMP-9 expression via Src, EGFR, Akt, p300, NF-kappa B, and histone acetylation in tracheal smooth muscle cells. FASEB J 2006;20:A1443.
42. Cai X, Chen Z, Pan X, Xia L, Chen P, Yang Y et al. Inhibition of angiogenesis, fibrosis and thrombosis by tetramethylpyrazine: mechanisms contributing to the SDF-1/CXCR4 axis. PLoS ONE 2014;9:e88176.
43. Liao X, Zhou X, Mak NK, Leung KN. Tryptanthrin inhibits angiogenesis by targeting the VEGFR2-mediated ERK1/2 signalling pathway. PLoS ONE 2013;8:e82294.
44. Nicosia RF. The aortic ring model of angiogenesis: a quarter century of search and discovery. J Cell Mol Med 2009;13:4113-36.
45. van Moorst M, Dass CR. Methods for co-culturing tumour and endothelial cells: systems and their applications. J Pharm Pharmacol 2011;63:1513-21.